Details
Description
Inclusion Criteria
Exclusion Criteria
Details
Title A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
IRB NRG-GY005
CC 16-395
Hospital Fairview, Hillcrest, Main Campus
Stage Recurrent/Relapsed
Phase Phase 2, Phase 3
Disease Fallopian Tube, Gynecologic, Ovarian, Peritoneal
Drug Cediranib, Olaparib
